Jazz Pharmaceuticals plc
JAZZ
$229.63
$0.440.19%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 19.06% | 10.09% | 6.74% | 2.14% | -0.46% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.06% | 10.09% | 6.74% | 2.14% | -0.46% |
| Cost of Revenue | 29.32% | 24.20% | 15.47% | 5.79% | 12.26% |
| Gross Profit | 18.13% | 8.80% | 5.71% | 1.70% | -1.48% |
| SG&A Expenses | -31.38% | 4.69% | 16.38% | 5.87% | 46.14% |
| Depreciation & Amortization | 11.59% | 6.82% | 6.93% | 4.43% | -0.85% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.50% | 1.95% | 10.05% | 0.29% | 15.93% |
| Operating Income | 1,066.54% | 40.28% | -3.34% | 9.79% | -124.73% |
| Income Before Tax | 371.26% | 56.46% | -95.52% | -633.40% | -3,640.25% |
| Income Tax Expenses | 134.27% | 108.57% | -1,568.09% | 43.99% | -252.54% |
| Earnings from Continuing Operations | 416.86% | 6.45% | 16.91% | -526.22% | -532.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 416.86% | 6.45% | 16.91% | -526.22% | -532.78% |
| EBIT | 1,066.54% | 40.28% | -3.34% | 9.79% | -124.73% |
| EBITDA | 211.74% | 25.99% | 1.01% | 8.41% | -48.31% |
| EPS Basic | 412.26% | 5.55% | 18.29% | -537.98% | -548.87% |
| Normalized Basic EPS | 512.67% | 58.88% | 2.43% | 26.45% | -329.02% |
| EPS Diluted | 391.45% | 3.21% | 19.28% | -571.31% | -550.41% |
| Normalized Diluted EPS | 486.45% | 55.37% | 3.81% | 40.02% | -329.02% |
| Average Basic Shares Outstanding | 1.48% | 0.86% | -1.17% | -2.68% | -2.46% |
| Average Diluted Shares Outstanding | 8.36% | 3.14% | -2.48% | -12.11% | -2.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |